Evaluating Technology-Based Fall Prevention Interventions (FaCT2)
Influence of Cognitive Training on Fall Prevention in At Risk Older Adults
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Washington
-
Seattle, Washington, United States, 98195
- University of Washington
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 65-89 years old
- speak and read English
- live within 30 miles of the University of Washington
- a score of 4 or higher on the Memory Impairment Screen (MIS-T)
- regular access to a computer with internet capability (whether at home, friend/family, community center, public library, or other)
- a positive response to any of the following three fall related questions: i) Have you had two or more falls in the prior 12 months? ii) Are you responding to the advertisement because of a recent fall? iii) Do you have difficulty with walking or balance?
- <53 seconds on 90 second balance test or gait speed <1m/sec.
Exclusion Criteria:
- current participation in formal cognitive training program
- currently bedridden or wheelchair dependent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Intervention
|
Web-based cognitive training intervention targeting specific cognitive tasks.
Subjects complete 3 training sessions per week with at least 24 hours in between sessions.
|
|
Other: Education
|
Subjects complete 16 web-based educational modules on healthy aging content.
Following each module, subjects complete a learning reflection.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Falls
Time Frame: 16 weeks
|
Falls and Injurious Falls as per Fall Calendar
|
16 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Disability
Time Frame: 8 weeks, 16 weeks, 20 weeks.
|
Gill Disability Scale
|
8 weeks, 16 weeks, 20 weeks.
|
|
Cognitive Assessment
Time Frame: 8 weeks, 16 weeks, 20 weeks
|
CANTAB Battery (Simple response time, one touch stockings of Cambridge, Stop Signal Task, Spatial Working Memory, Verbal Recognition Memory, Rapid Visual Information Processing)
|
8 weeks, 16 weeks, 20 weeks
|
|
Gait Assessment
Time Frame: 8 weeks, 16 weeks, 20 weeks
|
Assessment of Gait Parameters using APDM sensor system
|
8 weeks, 16 weeks, 20 weeks
|
|
Balance Assessment
Time Frame: 8 weeks, 16 weeks, 20 weeks
|
Assessment of Balance using APDM sensor system
|
8 weeks, 16 weeks, 20 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Hilaire Thompson, University of Washington
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- 50219
- R21NR015541 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Falls (Accidents) in Old Age
-
NCT04134988UnknownFalls (Accidents) in Old Age
-
NCT07112573RecruitingPsychotropic Drugs | Falls (Accidents) in Old Age
-
NCT06961812Not yet recruitingFall Prevention | Falls (Accidents) in Old Age
-
NCT06545539Not yet recruitingFall | Fall Injury | Falls (Accidents) in Old Age
-
NCT06961799RecruitingFalls (Accidents) in Old Age | Falls Risk | Community Dwelling Older Adults | Aged 65 Years or Older
-
NCT07273253CompletedFalls (Accidents) in Old Age | Malnutrition Elderly | Depression in Adults | Post-Traumatic Stress Disorder in Old Age | Frailty at Older Adults
-
NCT03961386UnknownFalls (Accidents) in Old Age
-
NCT03360305Completed
-
NCT07512323Not yet recruitingHypogonadal Males | Falls (Accidents) in Old Age | Frail Elderly Patients | Testosterone Replacement Therapy
-
NCT05106881Completed
Clinical Trials on Cognitive Training
-
NCT03860441CompletedEffects of Cognitive Intervention on Cognition, Mobility and Brain Electrocortical Activity (GIBKOP)Cognitive Impairment | Aging | Cognitive Decline | Motor Coordination or Function
-
NCT02184598UnknownAttention-deficit/Hyperactivity Disorder.
-
NCT05227495RecruitingVirtual Reality | Community-dwelling Elderly
-
NCT06524388Enrolling by invitationDiabetes Mellitus, Type 2 | Aging | Cognition
-
NCT06198530RecruitingMild Cognitive Impairment
-
NCT01279070CompletedIndication for Modification of Patient Cognitive Status
-
NCT03805620CompletedMild Cognitive Impairment
-
NCT03836963CompletedParkinson's Disease | Mild Cognitive Impairment
-
NCT04779671Recruiting